Breaking News

Sulzer Confirms Merger Talks With Dresser-Rand
Tweet TWEET

Illumina Launches BaseSpace® Apps

  Illumina Launches BaseSpace® Apps

Beta Phase Ends, Platform Enables E-Commerce for Developers with Introduction
                                 of iCredits™

Business Wire

SAN DIEGO -- May 16, 2013

Illumina, Inc. (NASDAQ:ILMN) today announced the full commercial availability
of BaseSpace, the Company’s genomics cloud computing and storage platform.
BaseSpace Apps is now out of beta status, and includes a full-fledged
e-commerce system that allows customers to quickly and easily purchase
Illumina and third-party bioinformatics applications (apps). BaseSpace
e-commerce transactions are based on BaseSpace iCredits, a medium of exchange
that can be purchased and spent within BaseSpace.

BaseSpace has rapidly become a valuable platform for bioinformatics app
developers. During the beta period, users launched individual BaseSpace apps
more than 4,000 times. Now, with BaseSpace iCredits, developers can easily add
e-commerce functionality to their apps, leveraging Illumina’s complete payment
solution.

“The commercial availability of BaseSpace Apps is an important milestone for
both Illumina customers and BaseSpace app developers. For customers, BaseSpace
has transitioned into a fully-supported bioinformatics platform; for BaseSpace
app developers, BaseSpace now has a comprehensive e-commerce capability that
enables them to monetize their efforts,” said Alex Dickinson, Illumina’s
Senior Vice President, Cloud Genomics. “With rapid adoption of BaseSpace by
users of Illumina’s high-throughput HiSeq® next-generation sequencing systems,
and the continued use of the platform by users of Illumina’s MiSeq® desktop
sequencing systems, the scale of growth potential for BaseSpace Apps is
increasing exponentially.”

“BaseSpace continues to attract a large number of app developers who can
rapidly make their bioinformatics tools available to thousands of Illumina
customers,” added Jordan Stockton, Illumina’s Director of Product Marketing,
Computational Biology. “BaseSpace is designed to support apps that enable
genomics research in diverse markets including cancer, microbiology, and
genetic disease.”

Through the BaseSpace ecosystem, a diverse collection of new apps are now
available for Illumina’s MiSeq and HiSeq systems. For example, Elsevier
Publishing, the world’s leading publisher of scientific and health
information, has released a BaseSpace app that enables users to submit data
directly into the peer-review publication process.

“We’re excited to be working with Illumina to accelerate the scientific
publication process,” said Bart Wacek, Executive Publisher, Elsevier Life
Sciences. “Through BaseSpace, scientists can directly submit their data and
manuscript to our Genomics Data journal, allowing the data review to be an
integral part of the peer-review process.”

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release contains forward-looking statements that involve risks and
uncertainties. Examples of forward-looking statements include, but are not
limited to, statements we make regarding the expected availability dates for
BaseSpace Apps and related data analysis applications and programs. Important
factors that could cause actual results to differ materially from those in any
forward-looking statements include challenges inherent in developing and
launching new products and services and the other factors that are detailed in
our filings with the Securities and Exchange Commission, including our most
recent filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this
release.

Contact:

Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
858-882-6822
pr@illumina.com
 
Press spacebar to pause and continue. Press esc to stop.